Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Transposagen, Janssen Enter CAR-T Therapy Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Transposagen, Janssen Enter CAR-T Therapy Research Pact

Janssen licenses Transposagen genome editing technologies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Transposagen Biopharmaceuticals, Inc. has entered into a research and worldwide license agreement with Janssen Biotech to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). CAR-T therapies have shown promise in early trials for the treatment of blood cancers and have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient.
 
Transposagen will use its genome editing technologies, including the piggyBac Footprint-Free Gene Editing System, to create the allogeneic CAR-T therapies. Janssen has exclusive rights to any CAR-T therapy jointly developed and has a non-exclusive research license to utilize Transposagen’s gene editing technologies for gene and cell therapy solutions. Transposagen will retain the rights to develop autologous CAR-T therapies and CAR-T therapies using Natural Killer (NK) cells or NK-like cells.
 
Transposagen will receive as much as $292 million per CAR-T therapeutic, which includes an up-front fee and potential development, regulatory, and commercial milestones. Transposagen will also receive royalties on sales of any CAR-T products commercialized by Janssen. Both companies will work together on preclinical research for a three-year term. Janssen will be responsible for manufacturing and commercialization.
 
“The research collaboration with Janssen will pair Transposagen’s cutting-edge gene editing and gene delivery technology and expertise with Janssen industry-leading technologies in the antibody and antibody alternative areas to create what may be the ideal CAR-T therapy,” said Eric Ostertag, president and chief executive officer of Transposagen.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics